Patients with Myelodysplastic Syndromes Treated with Azacitidine in Clinical Practice: The AVIDA® Registry | Aplastic Anemia and MDS International Foundation

Patients with Myelodysplastic Syndromes Treated with Azacitidine in Clinical Practice: The AVIDA® Registry

Journal Title: 
Leuk Lymphoma
Author(s): 
Grinblatt DL, Sekeres MA, Komrokji RS, Swern AS, Sullivan KA, Narang M
Primary Author: 
Grinblatt DL
Original Publication Date: 
Monday, June 23, 2014

ABSTRACT The AVIDA registry evaluated azacitidine usage and effectiveness in unselected MDS patients in community practice. Treating physicians made all treatment decisions. Hematologic improvement (HI) and transfusion independence (TI) assessments used IWG-2000 criteria. Enrolled were 421 MDS patients (n=228 IPSS lower-risk, n=106 higher-risk, 86 patients unclassified) from 105 U.S. sites. Median follow-up was 7.6 months (range: 0.1-27.6). HI and RBC TI rates were similar regardless of administration route or dosing schedule. Safety and tolerability were consistent with previous reports. The AVIDA registry data support azacitidine effectiveness and safety in lower- or higher-risk MDS patients treated in community practice.

Bone Marrow Diseases: